120 related articles for article (PubMed ID: 32558291)
1. Vemurafenib-related photosensitivity.
Eberlein B; Biedermann T; Hein R; Posch C
J Dtsch Dermatol Ges; 2020 Oct; 18(10):1079-1083. PubMed ID: 32558291
[TBL] [Abstract][Full Text] [Related]
2. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
[TBL] [Abstract][Full Text] [Related]
3. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib: an unusual UVA-induced photosensitivity.
Gelot P; Dutartre H; Khammari A; Boisrobert A; Schmitt C; Deybach JC; Nguyen JM; Seité S; Dréno B
Exp Dermatol; 2013 Apr; 22(4):297-8. PubMed ID: 23528218
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
6. Severe vemurafenib-induced photosensitivity in a 6-year-old boy.
Jew OS; Provini LE; Treat JR
Pediatr Dermatol; 2019 Jan; 36(1):e62-e63. PubMed ID: 30474875
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
8. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria.
Lim HW
Immunol Ser; 1989; 46():671-85. PubMed ID: 2488874
[TBL] [Abstract][Full Text] [Related]
11. Characterization of vemurafenib phototoxicity in a mouse model.
Boudon SM; Plappert-Helbig U; Odermatt A; Bauer D
Toxicol Sci; 2014 Jan; 137(1):259-67. PubMed ID: 24154489
[TBL] [Abstract][Full Text] [Related]
12. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro.
Piomelli S; Lamola AA; Poh-Fitzpatrick MF; Seaman C; Harber LC
J Clin Invest; 1975 Dec; 56(6):1519-27. PubMed ID: 1202082
[TBL] [Abstract][Full Text] [Related]
14. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
[TBL] [Abstract][Full Text] [Related]
16. Clothing as solar radiation protection.
Menter JM; Hatch KL
Curr Probl Dermatol; 2003; 31():50-63. PubMed ID: 12882019
[TBL] [Abstract][Full Text] [Related]
17. Profile of vemurafenib-induced severe skin toxicities.
Peuvrel L; Quéreux G; Saint-Jean M; Brocard A; Nguyen JM; Khammari A; Knol AC; Varey E; Dréno B
J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):250-7. PubMed ID: 26524690
[TBL] [Abstract][Full Text] [Related]
18. Drug-Induced Photosensitivity - a Continuing Diagnostic Challenge.
Lugović-Mihić L; Duvančić T; Ferček I; Vuković P; Japundžić I; Ćesić D
Acta Clin Croat; 2017 Jun; 56(2):277-283. PubMed ID: 29485795
[TBL] [Abstract][Full Text] [Related]
19. Delayed photosensitivity in a child with erythropoietic protoporphyria : a case report.
Kiberd J; Finlayson L
SAGE Open Med Case Rep; 2018; 6():2050313X18772125. PubMed ID: 29854403
[TBL] [Abstract][Full Text] [Related]
20. Case of late-onset erythropoietic protoporphyria with myelodysplastic syndrome who has homozygous IVS3-48C polymorphism in the ferrochelatase gene.
Suzuki H; Kikuchi K; Fukuhara N; Nakano H; Aiba S
J Dermatol; 2017 Jun; 44(6):651-655. PubMed ID: 28026050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
